There are 1,197 papers on atherosclerotic cardiovascular disease in aging research: 83 trials and 683 observational studies in people, 7 in animals, 1 in cells, 382 reviews. The newest story, Nov 19, 2026: “Higher urine ketone scores linked to lower artery disease risk”.
Statins were not clearly linked with atherosclerotic cardiovascular disease in humans (without type 2 diabetes, aged 75-84 years) (HR 0.94 (95% CI 0.86 to 1.04)).
“statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality”
Statins prevent atherosclerotic cardiovascular disease in humans.
“Statins remain the mainstay of pharmacotherapy for reducing concentrations of total cholesterol and low-density lipoproteins, as well as for preventing atherosclerotic cardiovascular disease.”
Statins prevent atherosclerotic cardiovascular disease in humans (primary prevention).
“sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population.”
Saturated fat intake was not clearly linked with atherosclerotic cardiovascular disease in humans (Bottom 3 quartiles of PGSLDL; without prevalent ASCVD) (HR 1.00, 95% CI 0.89–1.12).
“no association was observed among those in the bottom 3 quartiles (HR: 1.00; 95% CI: 0.89-1.12)”
HumansBottom 3 quartiles of PGSLDL; without prevalent ASCVD5% isocaloric increaseMedian follow-up: 10 years
Hormone replacement therapy was not clearly linked with atherosclerotic cardiovascular disease in humans (Free of baseline ASCVD, VTE, and cancer; initiation compared with non-initiation) (Adjusted HR 0.98, 95% CI 0.93–1.04).
“contemporary HRT was not associated with increased risk of VTE, ASCVD, or premature mortality”
HumansFree of baseline ASCVD, VTE, and cancer; initiation compared with non-initiationPredominantly contemporary oral and transdermal formulationsMean follow-up 12 years; up to 23 yearsfemalesn = 52,330
Pelacarsen showed no clear effect on atherosclerotic cardiovascular disease in humans (phase 3 Lp(a)HORIZON trial).
“topline results from the phase 3 Lp(a)HORIZON trial showed that pelacarsen, despite lowering Lp(a), did not reduce the primary composite cardiovascular endpoint.”
Fatty liver was not clearly linked with atherosclerotic cardiovascular disease in humans after further adjustment for apolipoprotein B (HR 1.39, 95% CI 0.91-2.13).
“The CVD association was attenuated to non-significance after further adjustment for apoB (HR 1.39, 95% CI 0.91-2.13, p = 0.134).”
Humansafter further adjustment for apolipoprotein B
Atherosclerotic cardiovascular disease is linked with higher circulating progenitor cells in ASCVD patients.
“Despite an increased number of circulating precursors in ASCVD patients, ASCVD impaired the colony forming capacity and the angiogenic properties of ECFC in a severity-dependent manner.”
Body mass index is linked with atherosclerotic cardiovascular disease in humans (mediating DI-GM and ASCVD association) (11.51% (95% CI: 2.54%-54.1%, P = 0.016)).
“BMI mediated 11.51% of the association between DI-GM and ASCVD (95% CI: 2.54%-54.1%, P = 0.016)”
Metabolic syndrome is linked with atherosclerotic cardiovascular disease in humans (63.4% mediated; indirect RR 1.29, 95% CI 1.13–1.48).
“with 63.4% of the association mediated through midlife MetS (indirect risk ratio: 1.29; 95% CI: 1.13-1.48).”
HumansMediation of the association between young-adulthood insulin resistance and later-life ASCVDMetabolic syndrome assessed at year 20; ASCVD events through year 35n = 3,622
Lipoprotein was not clearly linked with atherosclerotic cardiovascular disease in humans (MESA; elevated versus lower Lp(a), both without carotid plaque; similar findings in ARIC) (HR 1.04, 95% CI 0.73–1.48; absolute risk 3.86 events per 1000 person-years in MESA).
“there was no significantly increased ASCVD risk (HR 1.04, 0.73-1.48 in MESA)”
HumansMESA; elevated versus lower Lp(a), both without carotid plaque; similar findings in ARIC10 yearsn = 5,181
Gestational diabetes mellitus was not clearly linked with atherosclerotic cardiovascular disease in humans (Pregnancy-evidence cohort; APO subtype analysis).
“Gestational diabetes showed no clear association with ASCVD.”
HumansPregnancy-evidence cohort; APO subtype analysisfemales
Plasma atherosclerosis index is linked with atherosclerotic cardiovascular disease in humans (flavonoid intake to ASCVD risk) (11.3% proportion mediated).
“Mediation analysis suggested a small indirect effect through AIP, with an estimated proportion mediated of 11.3%.”
High-density lipoprotein cholesterol is linked with lower atherosclerotic cardiovascular disease in humans (apoB-HDL-C interaction test) (HR 0.95, 95% CI 0.93-0.96).
“The apoB-HDL-C interaction was significant: HR 0.95 (95% CI: 0.93-0.96; p < 0.001), consistent across sexes.”
KDM biological age acceleration is linked with atherosclerotic cardiovascular disease in humans (mediating proportion 29.8%) (29.8% mediating proportion).
“significant mediation roles of KDM.Accel and PhenoAge.Accel in the Cu-ASCVD association, with mediating proportions of 29.8% and 43.8%, respectively.”
Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (Primary prevention cohort; high lipoprotein(a)) (Incidence increase per 50 mg/dL higher lipoprotein(a): 2.7 per 1000 person-years (95% CI 2.2-3.2) at ages 70-79; 4.5 (3.7-5.4) at ages 80-100).
“individuals aged 70-100 with high lipoprotein(a) had the highest absolute risk of atherosclerotic cardiovascular disease.”
HumansPrimary prevention cohort; high lipoprotein(a)Median follow-up 12.5 yearsn = 18,322
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.05, 95% CI 1.02–1.08).
“The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”
Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (prior ASCVD diagnosis before admission, multivariable analysis) (OR 1.638; 95% CI 1.115–2.405).
“elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115–2.405; p = 0.012)”
Humansprior ASCVD diagnosis before admission, multivariable analysisn = 729
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (primary prevention cohort) (HR 1.12 to 1.18 per 50 mg/dL).
“Hazard ratios per 50 mg/dL higher lipoprotein(a) were similar across all age groups and sexes, ranging from 1.12 to 1.18”
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.23 (95% CI 1.19-1.27)).
“highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”
Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (Per 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization) (2% higher risk per 10 nmol/L genetically predicted Lp(a)).
“MR showed a 2% higher ASCVD risk per 10 nmol/L genetically predicted Lp(a) (P<2×10−16).”
HumansPer 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization
LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans (Patients genetically tested for familial hypercholesterolemia) (HR 1.17 per 1 mmol/L increase; 95% CI 1.13–1.22).
“LDL-C was significantly associated with the risk of future ASCVD”
HumansPatients genetically tested for familial hypercholesterolemiaPer 1 mmol/L increase in LDL-CMean follow-up 13.9 ± 9.8 yearsn = 2,327
LDL cholesterol lowers the risk of atherosclerotic cardiovascular disease in silico (lowering to 70 mg/dL or 55 mg/dL in adults with ASCVD and diabetes) (18.0% and 23.7% relative risk reduction).
“Predicted 3-year relative risk reductions were 18.0% and 23.7%, corresponding to 38,200 and 50,100 predicted preventable events, with LDL-C lowering to 70 mg/dL or 55 mg/dL, respectively”
In silicolowering to 70 mg/dL or 55 mg/dL in adults with ASCVD and diabetes3 yearsn = 131
Statins are associated with atherosclerotic cardiovascular disease in humans (active-comparator new-user design versus ezetimibe; propensity score overlap weighting) (HR 1.26, 95% CI 1.11-1.45).
“statin initiation was associated with higher risks of ASCVD (HR 1.26, 95% CI 1.11-1.45) and AnyDem (HR 1.66, 95% CI 1.16-2.38)”
Statins lower the risk of atherosclerotic cardiovascular disease in humans (primary and secondary prevention of cardiovascular events).
“Low-density lipoprotein (LDL) cholesterol-lowering therapies, such as statins, have consistently demonstrated robust efficacy in the primary and secondary prevention of cardiovascular events.”
Reviewprimary and secondary prevention of cardiovascular events
Statins lower the risk of atherosclerotic cardiovascular disease in individuals with HIV.
“these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen.”
Low-density lipoprotein cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans (high LDL-C (LDL-C >=4.1 mmol/L) with lowest RC level vs controls) (HR, 1.20 [95% CI, 1.02-1.41]).
“In contrast, in the high LDL-C group (LDL-C ≥4.1 mmol/L), even when RC was at the lowest level, ASCVD risk remained significantly higher than that of controls (HR, 1.20 [95% CI, 1.02-1.41]).”
Humanshigh LDL-C (LDL-C >=4.1 mmol/L) with lowest RC level vs controls12.8 years
Low-density lipoprotein cholesterol raises the risk of atherosclerotic cardiovascular disease in humans (familial hypercholesterolemia).
“Familial hypercholesterolemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C), leading to a high risk of early onset atherosclerotic cardiovascular disease (ASCVD).”
Low-density lipoprotein cholesterol raises the risk of atherosclerotic cardiovascular disease in combination with other risk factors.
“long-term exposure to the risk factor (LDL hypercholesterolemia), which, not adequately controlled and in combination with other risk factors, has favored the onset of major cardiovascular events.”
Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease in humans.
“The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality.”
Remnant cholesterol is associated with atherosclerotic cardiovascular disease in humans.
“Compared with participants with concordantly low lipid levels, those with elevated non-HDL-C or RC but normal LDL-C had significantly higher ASCVD risk.”
Humanschronic kidney disease; elevated remnant cholesterol but normal LDL cholesterol versus concordantly low lipid levelsmedian follow-up of 13.81 yearsn = 27,978
Remnant cholesterol is associated with atherosclerotic cardiovascular disease in humans (HR, 1.03 [95% CI, 0.93-1.13]).
“In the borderline-high LDL-C group (3.4 ≤ LDL-C < 4.1 mmol/L), those with the lowest RC levels showed no significant risk difference compared with controls (hazard ratio [HR], 1.03 [95% CI, 0.93-1.13])”
Humansborderline-high LDL-C (3.4 <= LDL-C < 4.1 mmol/L) with lowest RC levels (<0.5 mmol/L) vs controls12.8 years
Remnant cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans (categorical RC Q4 vs Q1) (HR 2.00, 95% CI 1.22–3.27).
Remnant cholesterol raises the risk of atherosclerotic cardiovascular disease in observational epidemiological and Mendelian randomization studies.
“Elevated plasma concentration of remnant cholesterol, the cholesterol in triglyceride-rich lipoproteins, is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)”
Reviewin observational epidemiological and Mendelian randomization studies
C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.36 (95% CI 1.30-1.43)).
“the highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”
C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (cumulative joint exposure G4 vs G1) (HR 2.17 (1.98, 2.37)).
“compared with G1, G2, G3, and G4 had a higher risk of ASCVD HR (95% CI) were 1.45 (1.30, 1.62), 1.80 (1.66, 1.95), and 2.17 (1.98, 2.37), respectively.”
C-reactive protein is associated with atherosclerotic cardiovascular disease in humans (HR 1.03 per 1.0 mg/L increase, 95% CI 1.02–1.05).
“Joint modeling revealed a significant time-dependent association of hs-CRP trajectory with incident ASCVD (HR 1.03 per 1.0 mg/L increase, 95% CI 1.02–1.05, P < 0.001).”
C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (adjusted HR 1.02, 95% CI 1.01–1.02).
“Each unit increase in hs-CRP was associated with greater ASCVD risk (adjusted hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.01–1.02, P < 0.001).”
IL-6 is associated with atherosclerotic cardiovascular disease in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.48, 95% CI 1.33–1.64).
“IL-6 at or above the median was associated with higher risks of atherosclerotic CVD (hazard ratio, 1.48; 95% CI, 1.33–1.64)”
HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894
IL-6 is linked with a higher risk of atherosclerotic cardiovascular disease in humans after adjusting for LE8 metrics and demographics (HR 1.54 [1.05-2.25], p = 0.03).
“Increased IL-6 was independently associated with ASCVD (HR 1.54 [1.05-2.25], p = 0.03)”
Humansafter adjusting for LE8 metrics and demographics12 yearsn = 1,869
LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.
“elevated low-density lipoprotein cholesterol (LDL-C) recognized as a causal factor and the primary target for the prevention of atherosclerotic cardiovascular disease (ASCVD)”
LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.
“Even younger individuals with a greater cumulative exposure to LDL-C, despite their age, may have a higher overall risk compared to older individuals with a lower cumulative exposure to LDL-C.”
Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (borderline PREVENT scores (5.0-7.5%)) (OR 1.9).
“observed 10y ASCVD rate moved from 4.8% (4.0-5.7%) to 8.8% (7.7-10.0%) in low (bottom 20%) versus high (top 20%) PRS individuals, an odds ratio of 1.9”
Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (highest tertile compared to lowest tertile) (RR 1.59, 95% CI 1.16–2.17).
“The high-risk PRS increased ASCVD risk by 59% (Risk Ratio=1.59;95% Confidence Interval:1.16-2.17) in the highest tertile for AAs”
Humanshighest tertile compared to lowest tertilen = 1,606
medRxiv : the preprint server for health sciences·Preprint
Polygenic risk score predicts atherosclerotic cardiovascular disease in European populations.
“Polygenic risk scores (PRS), which quantify this inherited susceptibility, have demonstrated strong predictive performance in European populations, with accumulating evidence supporting their use in clinical practice.”
Compared with the lowest-scoring group, the highest-scoring group had 24% lower relative risk of artery disease in men and 22% in women.Compared with the lowest-scoring group, the highest-scoring group had 24% lower relative risk of artery disease in men and 22% in women.
Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.
An observational analysis of 20,940 Women’s Health Initiative participants linked saturated fat more strongly to LDL cholesterol at higher levels of inherited cholesterol…An observational analysis of 20,940 Women’s Health Initiative participants linked saturated fat more strongly to LDL cholesterol at higher levels of inherited cholesterol risk.